文献速递头颈部肿瘤放疗

年轻头颈鳞癌患者放疗结局与风险因素的配对分析

Radiotherapy outcomes and risk factors for young patients with head-and-neck squamous cell carcinomas: a matched-pair analysis.
PubMed 文献 · Radiat Oncol · 2025-04-22

该研究分析2009至2021年两家大型癌症中心收治的≤45岁头颈鳞癌(HNSCC)患者,按TNM与肿瘤部位与>45岁患者配对,比较生存与治疗相关毒性。年轻队列中位OS为63个月,每日饮酒是多因素分析中OS降低的关键风险因素;与年长患者相比OS相似,但相对性别与年龄匹配一般人群的额外死亡风险达59倍,而≥45岁患者仅为5.9倍。PFS、LRC、DMFS组间无显著差异,年轻患者慢性毒性程度中等。

要点

  • ≤45岁HNSCC患者(化疗)放疗后中位OS为63个月。
  • 每日饮酒是多因素分析中OS降低的关键风险因素。
  • 年轻与年长患者OS、PFS、LRC、DMFS均无显著差异。

核心结论

  • ≤45岁接受(化疗)放疗的HNSCC患者肿瘤生存结局与年长患者相似。
  • 年轻患者慢性毒性较低,仍需进一步研究长期生活质量。

研究设计与样本

  • 2009至2021年两家大型癌症中心≤45岁接受放疗的HNSCC患者,按TNM和肿瘤部位与>45岁队列配对分析。
  • 共纳入99例患者。

主要发现

  • 年轻HNSCC队列中位OS为63个月。
  • 每日饮酒是多因素分析中OS降低的关键风险因素。
  • 年轻队列OS与年长患者相似,但相对性别与年龄匹配一般人群的额外死亡风险为59倍,≥45岁患者为5.9倍。
  • PFS、LRC、DMFS在年龄组间无显著差异。
  • 年轻HNSCC患者较高等级慢性毒性程度中等。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Head-and-neck squamous cell carcinomas (HNSCC) exhibit significant variations in incidence and outcomes across age groups. There is conflicting data on the oncological outcomes of younger HNSCC patients ≤ 45 years. This study analyzed clinical characteristics, treatment-related toxicities and survival rates of young HNSCC patients treated with (chemo)radiotherapy. METHODS: HNSCC patients ≤ 45 years treated with radiotherapy between 2009 and 2021 at two large cancer centers were analyzed and matched to a patient cohort > 45 years based on TNM and tumor localization. Overall (OS), progression-free (PFS) and metastasis-free (DMFS) survival and locoregional control (LRC) were compared and treatment-related toxicities were assessed. RESULTS: 99 patients were included in this analysis. Median OS of the young HNSCC cohort was 63 months. Daily alcohol consumption was identified as a key risk factor for reduced OS in the multivariate analysis. OS was similar in the young cohort compared to older patients, although the excess mortality risk compared to the sex- and age-matched general population amounted to 59-fold, while it was only 5.9-fold for patients ≥ 45 years. No significant differences were observed in PFS, LRC, or DMFS between age groups. Higher-grade chronic toxicities were moderate in young HNSCC patients. CONCLUSIONS: Young HNSCC patients ≤ 45 years treated with (chemo)radiation have similar rates of oncological survival outcomes compared to older patients. While chronic toxicities from (chemo)radiation are low, further research is needed to explore the long-term quality-of-life.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zou J, Rühle A, Schäfer H, et al. Radiotherapy outcomes and risk factors for young patients with head-and-neck squamous cell carcinomas: a matched-pair analysis. Radiat Oncol. 2025. PMID: 40264145. doi:10.1186/s13014-025-02631-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。